Do analysts recommend CALT or MANE?

Veradermics has a consensus target price of $153.00, suggesting a potential upside of 29.39%. Given Veradermics' stronger consensus rating and higher probable upside, analysts clearly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Veradermics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts rate CALT or INDV?

Indivior has a consensus target price of $45.17, suggesting a potential upside of 24.80%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Indivior 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86

Do analysts rate CALT or OGN?

Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 16.88%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts clearly believe Organon & Co. is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Organon & Co. 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71

Do analysts rate CALT or TARS?

Tarsus Pharmaceuticals has a consensus target price of $94.00, indicating a potential upside of 21.95%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tarsus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.70

Do analysts prefer CALT or ARQT?

Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 28.05%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Arcutis Biotherapeutics 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67

Calliditas Therapeutics AB (publ) (CALT) Competitors

$40.00 0.00 (0.00%)

As of 09/21/2026

Compare

CALT vs. MANE, INDV, OGN, TARS, and ARQT

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? Calliditas Therapeutics AB (publ)'s main competitors and comparable companies include Veradermics (MANE), Indivior (INDV), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

In the previous week, Veradermics had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Veradermics and 0 mentions for Calliditas Therapeutics AB (publ). Veradermics' average media sentiment score of 0.67 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Veradermics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Veradermics	Positive

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Veradermics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Veradermics	N/A	N/A	N/A

Veradermics has a consensus target price of $153.00, suggesting a potential upside of 29.39%. Given Veradermics' stronger consensus rating and higher probable upside, analysts clearly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Veradermics beats Calliditas Therapeutics AB (publ) on 8 of the 14 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Indivior has a consensus target price of $45.17, suggesting a potential upside of 24.80%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Indivior has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Indivior	$1.24B	3.45	$210M	$2.79	12.97

Indivior has a net margin of 26.65% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Indivior	26.65%	-283.11%	36.85%

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Indivior has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

In the previous week, Indivior had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 0.59 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Indivior	Positive

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Organon & Co. had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Organon & Co. and 0 mentions for Calliditas Therapeutics AB (publ). Organon & Co.'s average media sentiment score of 0.67 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Organon & Co.	Positive

Organon & Co. has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81

Organon & Co. has a net margin of 3.41% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Organon & Co.'s return on equity of 88.97% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Organon & Co.	3.41%	88.97%	6.03%

Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 16.88%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts clearly believe Organon & Co. is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Organon & Co. beats Calliditas Therapeutics AB (publ) on 12 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Tarsus Pharmaceuticals?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Tarsus Pharmaceuticals had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Tarsus Pharmaceuticals' average media sentiment score of 0.74 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Tarsus Pharmaceuticals	Positive

Tarsus Pharmaceuticals has a consensus target price of $94.00, indicating a potential upside of 21.95%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Tarsus Pharmaceuticals	$451.36M	7.49	-$66.42M	-$1.09	N/A

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Arcutis Biotherapeutics?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Arcutis Biotherapeutics had 10 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Arcutis Biotherapeutics	Positive

Arcutis Biotherapeutics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Arcutis Biotherapeutics	$376.07M	9.28	-$16.14M	$0.21	132.29

Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 28.05%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Arcutis Biotherapeutics' return on equity of 15.05% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALT vs. The Competition

Export

Metric	Calliditas Therapeutics AB (publ)	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.19B	$12.47B	$7.29B	$13.28B
Dividend Yield	N/A	2.63%	2.53%	12.80%
P/E Ratio	-21.62	792.42	275.15	25.85
Price / Sales	0.74	945.33	683.23	115.70
Price / Cash	N/A	15.08	28.04	34.72
Price / Book	37.74	10.76	10.73	6.45
Net Income	-$43.96M	$2.81B	$3.49B	$358.26M
7 Day Performance	N/A	3.32%	2.31%	2.34%
1 Month Performance	N/A	0.11%	-1.74%	-2.48%
1 Year Performance	N/A	4.55%	17.90%	6.41%

Calliditas Therapeutics AB (publ) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
MANE Veradermics	2.8886 of 5 stars	$104.15 +2.4%	$153.00 +46.9%	N/A	$4.25B	N/A	N/A	21	News Coverage Positive News
INDV Indivior	3.8919 of 5 stars	$34.22 -0.7%	$45.17 +32.0%	+57.8%	$4.07B	$1.24B	12.27	838	Dividend Announcement
OGN Organon & Co.	1.4082 of 5 stars	$13.68 +0.2%	$11.40 -16.6%	+31.0%	$3.58B	$6.22B	17.76	10,000	Positive News
TARS Tarsus Pharmaceuticals	3.1956 of 5 stars	$78.23 -2.2%	$94.00 +20.2%	+40.8%	$3.51B	$451.36M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. MANE, INDV, OGN, TARS, and ARQT

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Summary

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Summary

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Summary

How does Calliditas Therapeutics AB (publ) compare to Tarsus Pharmaceuticals?

Summary

How does Calliditas Therapeutics AB (publ) compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. MANE, INDV, OGN, TARS, and ARQT

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Which has stronger valuation & earnings, CALT or MANE?

Does the media prefer CALT or MANE?

Do insiders and institutionals have more ownership in CALT or MANE?

Is CALT or MANE more profitable?

Do analysts recommend CALT or MANE?

Summary

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Do insiders & institutionals hold more shares of CALT or INDV?

Do analysts rate CALT or INDV?

Which has better earnings and valuation, CALT or INDV?

Is CALT or INDV more profitable?

Which has more volatility & risk, CALT or INDV?

Does the media refer more to CALT or INDV?

Summary

How does Calliditas Therapeutics AB (publ) compare to Organon & Co.?

Does the media refer more to CALT or OGN?

Which has higher valuation and earnings, CALT or OGN?

Is CALT or OGN more profitable?

Do analysts rate CALT or OGN?

Which has more risk and volatility, CALT or OGN?

Do insiders and institutionals hold more shares of CALT or OGN?

Summary

How does Calliditas Therapeutics AB (publ) compare to Tarsus Pharmaceuticals?

Does the media refer more to CALT or TARS?

Do analysts rate CALT or TARS?

Is CALT or TARS more profitable?

Which has more risk & volatility, CALT or TARS?

Which has stronger earnings & valuation, CALT or TARS?

Do institutionals & insiders hold more shares of CALT or TARS?

Summary

How does Calliditas Therapeutics AB (publ) compare to Arcutis Biotherapeutics?

Does the media refer more to CALT or ARQT?

Which has stronger valuation and earnings, CALT or ARQT?

Do analysts prefer CALT or ARQT?

Which has more volatility and risk, CALT or ARQT?

Is CALT or ARQT more profitable?

Do institutionals and insiders hold more shares of CALT or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools